关注并星标CPHI制药在线2025年10月11日,国家药监局官网显示,和美药业研发的1类新药“莫米司特”正式获批上市,用于治疗斑块状银屑病。这不仅是中国首个自主研发的PDE4抑制剂,也标志着国产创新药在自身免疫疾病领域迈出了关键一步。一、国产 PDE4 “首秀” 的硬核背景莫米司特(Hemay005)是一款由和美药业自主研发的 1 类新药,属于磷酸二酯酶 4(PDE4)小分子抑制剂。PDE4 在人...
Source Link关注并星标CPHI制药在线2025年10月11日,国家药监局官网显示,和美药业研发的1类新药“莫米司特”正式获批上市,用于治疗斑块状银屑病。这不仅是中国首个自主研发的PDE4抑制剂,也标志着国产创新药在自身免疫疾病领域迈出了关键一步。一、国产 PDE4 “首秀” 的硬核背景莫米司特(Hemay005)是一款由和美药业自主研发的 1 类新药,属于磷酸二酯酶 4(PDE4)小分子抑制剂。PDE4 在人...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.